DA
SRPT icon

Duality Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Duality Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28,830
Closed -$2.78M – 736
2023
Q4 		$2.78M Buy
+28,830
New +$2.77M 0.29% 111
2023
Q3 		– Sell
-2,120
Closed -$243K – 705
2023
Q2 		$243K Sell
2,120
-17,001
-89% -$2.19M 0.03% 469
2023
Q1 		$2.64M Sell
19,121
-2,341
-11% -$304K 0.3% 128
2022
Q4 		$2.78M Buy
21,462
+19,166
+835% +$2.22M 0.32% 95
2022
Q3 		$254K Sell
2,296
-9,420
-80% -$949K 0.03% 476
2022
Q2 		$878K Buy
11,716
+2,965
+34% +$218K 0.09% 377
2022
Q1 		$684K Buy
+8,751
New +$670K 0.07% 417
2021
Q1 		– Sell
-5,210
Closed -$888K – 687
2020
Q4 		$888K Buy
5,210
+2,340
+82% +$347K 0.07% 365
2020
Q3 		$403K Sell
2,870
-7,553
-72% -$1.15M 0.03% 499
2020
Q2 		$1.67M Buy
+10,423
New +$1.42M 0.15% 191
2019
Q4 		– Sell
-129,950
Closed -$9.79M – 435
2019
Q3 		$9.79M Buy
+129,950
New +$15.3M 0.55% 38

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Duality Advisers's SRPT Position: Q1 2024 in Review

Duality Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 28,830 shares — an estimated $2.78M sold.

Duality Advisers first reported a position in SRPT in Q3 2019 and held it in 11 quarters. The position peaked at $9.79M in Q3 2019. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Duality Advisers reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Duality Advisers sold 28,830 Sarepta Therapeutics shares in Q1 2024, an estimated $2.78M.
  • Duality Advisers first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 11 quarters.
  • Duality Advisers's Sarepta Therapeutics position peaked at $9.79M in Q3 2019.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Duality Advisers's 13F filing for Q1 2024, filed 6 May 2024.